


Supplemental Figure S1



Imaging of the patients at day 28 of cediranib treatment shows partial response (i.e.: reduction of tumor volume more than 50%) in all patients except patient P3 based on T1 post contrast. Patient P3 shows stable disease at 28 days. At the end of the cediranib treatment when compared to day 28 imaging, patients P2 and P5 show clear progressive disease (increase by 25%) and P4 is suggestive of progression (20% increase). Patient P3 shows partial response at the end of the study (top panel).

Patients P1, P2 and P4 show increase of FLAIR signal at the end of the study, which might suggest increased infiltrating disease (bottom panel).